Therefore, it might be speculated that depending on the PD pathology stage, clusterin impact might be initially beneficial, but in the more advanced steps (associated with the robust accumulation of toxic α-synuclein agglomerates) the effects of clusterin may even stimulate neurodegeneration. This evidence concerns the gene CLU and Parkinson disease.